CEO, Rezo Therapeutics
Nadir Mahmood, Ph.D., is the Chief Executive Officer of Rezo Therapeutics. His experience spans corporate development, operations, finance, project management and fundraising. Prior to joining Rezo, Nadir was Chief Financial and Business Officer at Nkarta, where he played a critical role in building the company and raising over $600 million across private and public financings. Earlier in his career, Nadir served as Senior Director, Corporate Development at Second Genome, and as Staff Scientist at Kythera Biopharmaceuticals (acquired by Allergan). He has also worked in equity research at Goldman Sachs.
Nadir received a B.S. in biochemistry from the University of Texas at Austin and a Ph.D. in cell regulation from the University of Texas Southwestern Medical Center, and completed postdoctoral studies at the Scripps Research Institute in La Jolla, CA.